Abstract 572P
Background
Lung cancer was the leading cause of mortality in 2022, with 38.4% of patients having non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. EGFR tyrosine kinase inhibitors (TKIs) are the first-line treatment for EGFR-mutated NSCLC. A limited number of patients achieved five-year survival. This retrospective study aimed to provide real-world evidence and explore the factors affecting the five-year survival of patients with EGFR-mutated NSCLC.
Methods
This study included patients with EGFR-mutated NSCLC treated in Chang Gung Memorial Hospitals between 2011 and 2016, ensuring at least five years of follow-up or mortality. Odds ratios (ORs) were calculated using univariate and multivariate analyses. A scoring system based on a logistic regression model was designed to evaluate factor weightings on patients’ five-year survival. Their overall survival probability was estimated using the Kaplan-Meier model. The model’s accuracy was assessed using the area under the receiver operating characteristic curve (AUC).
Results
Of 1,873 enrolled patients, 185 were lost to follow-up within five years, leaving 1,787 for analysis. Of patients achieving five-year survival, more were female, age 65 years, had performance scores of 0∼1, no metastases, and adequate objective responses and disease control. A scoring system was developed by assigning points to each prognostic factor associated with increased risk of not achieving five-year survival: age > 65 years (1 point); performance score of 2∼4 (2 points); stage IV disease (1 point); liver (2 points), bone (1 point), or pleura (1 point) metastasis; and poor disease control (2 points). In the Kaplan-Meier model, the estimated five-year survival rate was 39.4%, 13.0%, 7.2%, and 2.2% for the low-risk (0∼1 point), intermediate-risk (2 points), high-risk (3 points), and very-high-risk (4∼10 points) groups, respectively. The prediction model’s AUC was 0.787 (95% CI: 0.752∼0.821), indicating fair accuracy.
Conclusions
We proposed a scoring system based on real-world data for predicting the five-year survival of patients with EGFR-mutated NSCLC treated with EGFR-TKIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chang Gung Memorial Hospital (Linkou Branch).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract